​

MoonLake Immunotherapeutics (MLTX) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChartTranscripts

MLTX Stock Forecast

MoonLake Immunotherapeutics (MLTX) stock forecast, based on 17 Wall Street analysts, predicts a 12-month average price target of $19.88, with a high of $35.00 and a low of $8.00. This represents a 16.74% increase from the last price of $17.03.

$5 $17 $29 $41 $53 $65 High: $35 Avg: $19.88 Low: $8 Last Closed Price: $17.03

MLTX Stock Rating

MoonLake Immunotherapeutics stock's rating consensus is Buy, based on 17 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 13 Buy (76.47%), 2 Hold (11.76%), 2 Sell (11.76%), and 0 Strong Sell (0.00%).

Buy
Total 17 2 2 13 0 Strong Sell Sell Hold Buy Strong Buy

MLTX Price Target Upside V Benchmarks

TypeNameUpside
StockMoonLake Immunotherapeutics16.74%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts1515
Avg Price Target$35.00$29.20$25.93
Last Closing Price$17.03$17.03$17.03
Upside/Downside105.52%71.46%52.26%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Mar, 261933-16
Feb, 261943-17
Jan, 261862-17
Dec, 251862-17
Nov, 251862-17
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Feb 24, 2026Oppenheimer$35.00$18.6887.37%105.52%
Jan 14, 2026Goldman Sachs$10.00$17.41-42.56%-41.28%
Jan 09, 2026H.C. Wainwright$32.00$14.34123.15%87.90%
Jan 09, 2026UBS$24.00$14.3467.36%40.93%
Jan 08, 2026UBS$45.00$14.38212.93%164.24%
Nov 21, 2025H.C. Wainwright$26.00$13.00100.00%52.67%
Nov 06, 2025Oppenheimer$30.00$10.29191.55%76.16%
Nov 03, 2025Raghuram SelvarajuH.C. Wainwright$30.00$10.10197.03%76.16%
Oct 07, 2025Oppenheimer$25.00$8.66188.68%46.80%
Sep 30, 2025Goldman Sachs$7.00$7.17-2.37%-58.90%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Feb 24, 2026OppenheimerOutperformOutperformhold
Feb 09, 2026BTIGBuyBuyhold
Jan 14, 2026Goldman SachsMixedSelldowngrade
Jan 09, 2026H.C. WainwrightBuyBuyhold
Jan 09, 2026BTIGNeutralBuyupgrade
Jan 08, 2026UBSBuyBuyhold
Nov 06, 2025OppenheimerOutperformOutperformhold
Nov 03, 2025H.C. WainwrightNeutralBuyupgrade
Oct 29, 2025CitigroupNeutralSelldowngrade
Oct 02, 2025H.C. WainwrightBuyNeutraldowngrade

Financial Forecast

EPS Forecast

$-6 $-5 $-4 $-3 $-2 $-1 $0 $1 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-0.73$-1.89$-3.53---
Avg Forecast$-0.90$-1.79$-2.77$-3.33$-3.63$0.80
High Forecast$-0.84$-1.61$-2.00$-2.09$-1.92$0.80
Low Forecast$-0.93$-1.92$-3.39$-4.31$-5.97$0.80
Surprise %-18.89%5.59%27.44%---

Revenue Forecast

$100M $210M $320M $430M $540M $650M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported------
Avg Forecast----$115.80M$645.41M
High Forecast----$120.20M$645.41M
Low Forecast----$111.40M$645.41M
Surprise %------

Net Income Forecast

$-300M $-230M $-160M $-90M $-20M $50M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-36.01M$-118.94M$-229.10M---
Avg Forecast$-43.46M$-80.77M$-132.53M$-157.26M$-267.54M$39.13M
High Forecast$-41.39M$-79.04M$-98.31M$-102.62M$-94.19M$39.13M
Low Forecast$-45.53M$-94.16M$-166.76M$-211.90M$-293.19M$39.13M
Surprise %-17.15%47.26%72.86%---

MLTX Forecast FAQ

Is MoonLake Immunotherapeutics stock a buy?

MoonLake Immunotherapeutics stock has a consensus rating of Buy, based on 17 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 13 Buy, 2 Hold, 2 Sell, and 0 Strong Sell, reflecting a consensus that MoonLake Immunotherapeutics is a favorable investment for most analysts.

What is MoonLake Immunotherapeutics's price target?

MoonLake Immunotherapeutics's price target, set by 17 Wall Street analysts, averages $19.88 over the next 12 months. The price target range spans from $8 at the low end to $35 at the high end, suggesting a potential 16.74% change from the previous closing price of $17.03.

How does MoonLake Immunotherapeutics stock forecast compare to its benchmarks?

MoonLake Immunotherapeutics's stock forecast shows a 16.74% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for MoonLake Immunotherapeutics over the past three months?

  • March 2026: 6.25% Strong Buy, 56.25% Buy, 18.75% Hold, 18.75% Sell, 0% Strong Sell.
  • February 2026: 5.88% Strong Buy, 52.94% Buy, 23.53% Hold, 17.65% Sell, 0% Strong Sell.
  • January 2026: 5.88% Strong Buy, 47.06% Buy, 35.29% Hold, 11.76% Sell, 0% Strong Sell.

What is MoonLake Immunotherapeutics’s EPS forecast?

MoonLake Immunotherapeutics's average annual EPS forecast for its fiscal year ending in December 2026 is $-3.33, marking a -5.67% decrease from the reported $-3.53 in 2025. Estimates for the following years are $-3.63 in 2027, and $0.8 in 2028.

What is MoonLake Immunotherapeutics’s revenue forecast?

MoonLake Immunotherapeutics's average annual revenue forecast for its fiscal year ending in December 2026 is $0, reflecting a 0% decrease from the reported $0 in 2025. The forecast for 2027 is $115.8M, and $645.41M for 2028.

What is MoonLake Immunotherapeutics’s net income forecast?

MoonLake Immunotherapeutics's net income forecast for the fiscal year ending in December 2026 stands at $-157M, representing a -31.36% decrease from the reported $-229M in 2025. Projections indicate $-268M in 2027, and $39.13M in 2028.